-
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
1 We have investigated the disposition and metabolism of sulphasalazine (SASP) in eight adults with and without inflammatory bowel disease. 2 SASP is poorly absorbed (less than 12%) and the half-time measured in the serum, 10.2 h, is probably the half-time of absorption and therefore an overestimate of the true half-time. The apparent volume of distribution is low (less than 9 l). Renal and biliary clearance rates are low (5.5 and 2.1 ml min-1 respectively) probably due to a high degree of protein binding. Of the absorbed SASP, two thirds is excreted in the urine and one third in the bile. 3 Most of the SASP reaches the colon and is there split by bacteria, forming sulphapyridine (SP) and 5-aminosalicylic acid (5-ASA). 4 SP is almost completely absorbed and, with its metabolites, is excreted in the urine (SP renal clearance rate 32.1 ml min-1). There is no enterohepatic recirculation. 5 Of the 5-ASA released in the colon at least 25% is absorbed and rapidly eliminated in the urine after acetylation. At least 50% is eliminated in the faeces. 6 There are no differences in disposition characteristics when comparing patients with and without inflammatory bowel disease but the metabolism of SASP is markedly reduced in patients taking antibiotics and after removal of the large bowel.
PMID: 6121576 [PubMed - indexed for MEDLINE]
PMCID: PMC1402052
-
Cited by 8 PubMed Central articles
-
Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.
van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Scheffer GL, Scheper RJ, Assaraf YG, Jansen G.
Ann Rheum Dis. 2004 Feb; 63(2):131-7.
[Ann Rheum Dis. 2004]
-
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.
Willoughby CP, Aronson JK, Agback H, Bodin NO, Truelove SC.
Gut. 1982 Dec; 23(12):1081-7.
[Gut. 1982]
-
Specific measurement of 5-aminosalicylic acid and its acetylated metabolite in human bile.
Fischer C, Maier K, Klotz U.
Br J Clin Pharmacol. 1983 Feb; 15(2):273-4.
[Br J Clin Pharmacol. 1983]
- » See all...
Patient Drug Information
-
Sulfasalazine (Azulfidine® , Azulfidine® EN-tabs® )
Sulfasalazine is used to treat bowel inflammation, diarrhea (stool frequency), rectal bleeding, and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed. Sulfasalazine delayed-re...